Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
Public ClinicalTrials.gov record NCT04002674. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies (DLB)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Dementia with Lewy Bodies (DLB) is an alphasynucleinopathy and the second most common form of dementia in the elderly. DLB shares striking neuropathological and clinical similarities with both Parkinson's disease (PD) and Alzheimer's disease (AD). Nilotinib (Tasigna®, AMN107, Novartis, Switzerland) is approved by the FDA and is well tolerated for CML treatment at oral doses of 600-800mg daily. The Investigators propose to perform a phase II randomized, double blinded, placebo controlled study to evaluate the impact of Nilotinib in patients with DLB.
Study identification
- NCT ID
- NCT04002674
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 25 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2019
- Primary completion
- Apr 29, 2025
- Completion
- Apr 29, 2025
- Last update posted
- Jun 11, 2026
2019 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Dementia With Lewy Bodies trials
Other public records listing Dementia With Lewy Bodies. Sorted by last update posted; newest first. Not a recommendation.
- NCT06389032: PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia Active, not recruiting
- NCT04246437: [18F]F-DOPA Imaging in Patients With Autonomic Failure Recruiting
- NCT04760860: Terazosin for Dementia With Lewy Bodies Not yet recruiting
- NCT07284290: Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia Recruiting
- NCT05222386: Community Outreach for Palliative Engagement -- Parkinson Disease Active, not recruiting
- NCT06098612: PET Imaging Evaluation of [11C]SY08 Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04002674, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2026 · Synced Sep 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04002674 live on ClinicalTrials.gov.